AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote monitoring policies.
|Articles|June 7, 2013
Evidence-Based Tack Drives HF Guidelines
Advertisement
An update to guidelines for managing heart failure emphasizes evidence-based therapy, according to the document from the American College of Cardiology (ACC) and the American Heart Association.
In particular, the authors introduced a new designation for optimal treatment called guideline-directed medical therapy (GDMT).
"This important 'call-out' of GDMT should be especially helpful for primary care physicians and physician extenders involved in the care of patients with heart failure," noted writing committee chair Clyde Yancy, MD, chief of cardiology at Northwestern University Feinberg School of Medicine in Chicago, in a statement.
Read the full story here:
Source: Med Page Today
Advertisement
Related to this article
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
Advertisement
Advertisement
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
3
Drug Price Drives Value of MASH Therapies More Than Efficacy
4
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
5